Novel strategies for the treatment of grass pollen-induced allergic rhinitis

References

• Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The international study of asthma and allergies in childhood (ISAAC) steering committee. Lancet. 1998 Apr 25;351(9111):1225–1232.
   PubMed Web of Science ®Google Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004 Nov;24(5):758–764. doi:10.1183/09031936.04.00013904.
   PubMed Web of Science ®Google Scholar
• Cox L. Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck Surg. 2015 Jun;23(3):247–254. doi:10.1097/MOO.0000000000000150.
   PubMed Web of Science ®Google Scholar
• Cardell LO, Olsson P, Andersson M, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. doi:10.1038/npjpcrm.2015.82.
   PubMed Web of Science ®Google Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015 Sep;136(3):556–568.
   PubMed Web of Science ®Google Scholar
• Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013 May;131(5):1361–1366. doi:10.1016/j.jaci.2013.02.013.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63(Suppl 86):8–160. doi:10.1111/j.1398-9995.2007.01620.x.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17. doi:10.1186/s40413-015-0063-2.
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008 Jul 24;454(7203):445–454.
   PubMed Web of Science ®Google Scholar
• Hatzler L, Panetta V, Lau S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012 Oct;130(4):894–901e5. doi:10.1016/j.jaci.2012.05.053.
   PubMed Web of Science ®Google Scholar
• Hatzler L, Panetta V, Illi S, et al. Parental hay fever reinforces IgE to pollen as pre-clinical biomarker of hay fever in childhood. Pediatr Allergy Immunol. 2014 Jun;25(4):366–373. doi:10.1111/pai.12248.
   PubMed Web of Science ®Google Scholar
• Bloemen K, Verstraelen S, Van Den Heuvel R, et al. The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol Lett. 2007 Oct 31;113(1):6–18.
   PubMed Web of Science ®Google Scholar
• Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004 Jun 7;199(11):1567–1575.
   PubMed Web of Science ®Google Scholar
• Didier A, Wahn U, Horak F, et al. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014 Oct;10(10):1309–1324. doi:10.1586/1744666X.2014.957677.
   PubMed Web of Science ®Google Scholar
• Valero A, Chivato T, Justicia JL, et al. Diagnosis and treatment of grass pollen-induced allergic rhinitis in specialized current clinical practice in Spain. Allergy Asthma Proc. 2011 Sep-Oct;32(5):384–389. doi:10.2500/aap.2011.32.3480.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. doi:10.1186/1939-4551-7-6.
   PubMedGoogle Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013 May;131(5):1288–96e3. doi:10.1016/j.jaci.2013.01.049.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012 Nov;130(5):1097–107 e2. doi:10.1016/j.jaci.2012.08.012.
   PubMed Web of Science ®Google Scholar
• Petersen KD, Kronborg C, Larsen JN, et al. Patient related outcomes in a real life prospective follow up study: allergen immunotherapy increase quality of life and reduce sick days. World Allergy Organ J. 2013;6(1):15. doi:10.1186/1939-4551-6-15.
   PubMedGoogle Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug;62(8):943–948. doi:10.1111/j.1398-9995.2007.01451.x.
   PubMed Web of Science ®Google Scholar
• Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004 Oct;114(4):851–857. doi:10.1016/j.jaci.2004.07.012.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012 Mar;129(3):717–25e5. doi:10.1016/j.jaci.2011.12.973.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.
   PubMed Web of Science ®Google Scholar
• Nelson H, Cartier S, Allen-Ramey F, et al. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):256–66 e3.
   PubMed Web of Science ®Google Scholar
• Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009 Dec;103(6):451-459; quiz 59-61, 95. doi:10.1016/S1081-1206(10)60259-1.
   Web of Science ®Google Scholar
• Lombardi C, Incorvaia C, Braga M, et al. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy. 2009 Jun;64(6):849–854. doi:10.1111/j.1398-9995.2009.02063.x.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med. 2015 Aug;175(8):1301–1309.
   PubMed Web of Science ®Google Scholar
• Uermosi C, Zabel F, Manolova V, et al. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy. 2014 Mar;69(3):338–347. doi:10.1111/all.12327.
   PubMed Web of Science ®Google Scholar
• Novak N, Mete N, Bussmann C, et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol. 2012 Nov;130(5):1153–58e2. doi:10.1016/j.jaci.2012.04.039.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest. 2014 Nov;124(11):4678–4680. doi:10.1172/JCI78891.
   PubMed Web of Science ®Google Scholar
• van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013 Apr;131(4):1204–1212. doi:10.1016/j.jaci.2013.01.014.
   PubMed Web of Science ®Google Scholar
• Palomares O, Ruckert B, Jartti T, et al. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol. 2012 Feb;129(2):510-520, 20 e1-9. doi:10.1016/j.jaci.2011.09.031.
   Web of Science ®Google Scholar
• Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2. doi:10.1186/2045-7022-2-2.
   PubMedGoogle Scholar
• Santos AF, James LK, Bahnson HT, et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. 2015 May;135(5):1249–1256. doi:10.1016/j.jaci.2015.01.012.
   PubMed Web of Science ®Google Scholar
• Skoner DP, Blaiss MS, Dykewicz MS, et al. The allergies, immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients’ experience with allergen immunotherapy. Allergy Asthma Proc. 2014 May-Jun;35(3):219–226. doi:10.2500/aap.2014.35.3752.
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1–S55. doi:10.1016/j.jaci.2010.09.034.
   PubMed Web of Science ®Google Scholar
• Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May;117(5):1021–1035. doi:10.1016/j.jaci.2006.02.040.
   PubMed Web of Science ®Google Scholar
• Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol. 2008 Jul;101(1):96–100. doi:10.1016/S1081-1206(10)60841-1.
   PubMed Web of Science ®Google Scholar
• Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol. 2012 Jul-Aug;2(4):280–284.
   PubMed Web of Science ®Google Scholar
• Kiel MA, Roder E, Gerth Van Wijk R, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013 Aug;132(2):353–60 e2. doi:10.1016/j.jaci.2013.03.013.
   PubMed Web of Science ®Google Scholar
• Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004 Mar;4(3):211–222. doi:10.1038/nri1310.
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009 Nov;124(5):997–1002. doi:10.1016/j.jaci.2009.07.019.
   PubMed Web of Science ®Google Scholar
• Senti G, Von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012 Jan;129(1):128–135. doi:10.1016/j.jaci.2011.08.036.
   PubMed Web of Science ®Google Scholar
• Senti G, Von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy. 2015 Jun;70(6):707–710. doi:10.1111/all.12600.
   PubMed Web of Science ®Google Scholar
• Rotiroti G, Shamji M, Durham SR, et al. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol. 2012 Oct;130(4):918–24 e1. doi:10.1016/j.jaci.2012.06.052.
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Ehl S, Aichele P, et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997 Apr;156:199–209.
   PubMed Web of Science ®Google Scholar
• Johansen P, Senti G, Martinez Gomez JM, et al. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol. 2005 Dec;35(12):3591–3598. doi:10.1002/eji.200535076.
   PubMed Web of Science ®Google Scholar
• Johansen P, Senti G, Martinez Gomez JM, et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy. 2005 Dec;35(12):1591–1598. doi:10.1111/j.1365-2222.2005.02384.x.
   PubMed Web of Science ®Google Scholar
• Johansen P, Mohanan D, Martinez-Gomez JM, et al. Lympho-geographical concepts in vaccine delivery. J Control Release. 2010 Nov 20;148(1):56–62.
   PubMed Web of Science ®Google Scholar
• Martinez-Gomez JM, Johansen P, Rose H, et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy. 2009 Jan;64(1):172–178. doi:10.1111/j.1398-9995.2008.01812.x.
   PubMed Web of Science ®Google Scholar
• Martinez-Gomez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150(1):59–65. doi:10.1159/000210381.
   PubMed Web of Science ®Google Scholar
• Mohanan D, Slutter B, Henriksen-Lacey M, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010 Nov 1;147(3):342–349.
   PubMed Web of Science ®Google Scholar
• Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993 Mar;91(3):709–722.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908–17912.
   PubMed Web of Science ®Google Scholar
• Hylander T, Latif L, Petersson-Westin U, et al. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412–420.
   PubMed Web of Science ®Google Scholar
• Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013 Nov;132(5):1248–52e5. doi:10.1016/j.jaci.2013.07.033.
   PubMed Web of Science ®Google Scholar
• Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17(1):10. doi:10.1186/s12931-016-0324-9.
   PubMed Web of Science ®Google Scholar
• Patterson AM, Bonny AE, Shiels WE 2nd, et al. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016 Feb;116(2):168–170.
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290–1296. doi:10.1016/j.jaci.2012.02.026.
   PubMed Web of Science ®Google Scholar
• Kundig TM, Johansen P, Bachmann MF, et al. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930–931. doi:10.1016/j.jaci.2013.11.036.
   PubMed Web of Science ®Google Scholar
• Mansson A, Bachar O, Adner M, et al. Leukocyte phenotype changes induced by specific immunotherapy in patients with birch allergy. J Investig Allergol Clin Immunol. 2010;20(6):476–483.
   PubMed Web of Science ®Google Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb;137(2):358–368. doi:10.1016/j.jaci.2015.12.1300.
   PubMed Web of Science ®Google Scholar
• Epstein TG, Liss GM, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):161–167. doi:10.1016/j.jaip.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2007 Jul;99(1):82–86. doi:10.1016/S1081-1206(10)60626-6.
   PubMed Web of Science ®Google Scholar
• Klimek L, Uhlig J, Mosges R, et al. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy. 2014 Dec;69(12):1629–1638. doi:10.1111/all.12513.
   PubMed Web of Science ®Google Scholar
• Kepil Ozdemir S, Sin BA, Guloglu D, et al. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response? Int Arch Allergy Immunol. 2014;164(3):237–245. doi:10.1159/000365628.
   PubMed Web of Science ®Google Scholar
• Cox L. Advantages and disadvantages of accelerated immunotherapy schedules. J Allergy Clin Immunol. 2008 Aug;122(2):432–434. doi:10.1016/j.jaci.2008.06.007.
   PubMed Web of Science ®Google Scholar
• Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010 Jan;104(1):79–85. doi:10.1016/j.anai.2009.11.010.
   PubMed Web of Science ®Google Scholar
• Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013 Jul;17(27):vi,xi-xiv, 1-322. doi:10.3310/hta17270.
   PubMed Web of Science ®Google Scholar